Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. In the SOD1 model of ALS we found loss of the unique molecular signature that characterizes microglia in association with increased expression of miR-155. There was loss of unique microglial molecules P2ry12, Tmem119, Olfml3, microglial transcription factors Egr1, Atf3, Jun, Fos, Mafb and upstream regulators Csf1r, Tgfb1 and Tgfbr1 essential for microglial survival. Major microglia biological functions including phagocytosis were suppressed. Genetic ablation of miR-155 increased survival in SOD1 mice and reversed abnormal microglial and monocyte molecular signatures. We found increased expression of miR-155 in the spinal cord of ALS subjects. Dysregulated proteins in SOD1 spinal cord that we identified in human ALS spinal cord and CSF were restored in SOD1 G93A /miR-155 −/− mice. Treatment with anti-miR-155 injected systemically or into the CSF prolonged survival and derepressed microglial miR-155 targeted genes. Our findings identify a new avenue for immune based therapy of ALS by targeting miR-155. Many developmental disorders such as Autism and Schizophrenia involve both cortical and subcortical structures, our central hypothesis, is that some of the abnormalities in cerebral cortex structure and function that underlie developmental disorders result from an early insult to the thalamus, which in turn leads to maldevelopment of the cerebral cortex.
ISDN2014 0028
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